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ABSTRACT
This article considers the component of the right to the highest standard of health that relates to
medicines, including essential medicines. Using the right-to-health analytical framework that has
been developed in recent years, the first section focuses on the responsibilities of States. The second
section provides a brief introduction to the responsibilities of pharmaceutical companies.
Original in English.
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THE HUMAN RIGHT TO MEDICINES
A. Introduction
Almost 2 billion people lack access to essential medicines.1 This deprivation causes
immense and avoidable suffering: ill health, pain, fear, loss of dignity and life.2
Improving access to existing medicines could save 10 million lives each year, 4
million of them in Africa and South-East Asia.3 Besides deprivation, gross inequity
in access to medicines remains the overriding feature of the world pharmaceutical
situation.4 Average per capita spending on medicines in high income countries is
100 times higher than in low-income countries: about US$ 400 compared with
US$ 4. WHO estimates that 15 per cent of the world’s population consumes
over 90 per cent of the world’s production of pharmaceuticals.5
Existing national and international policies, rules and institutions give rise
to these massive deprivations and inequalities. National supply systems for
medicines often do not reach those living in poverty. If they do, the medicines
are often unaffordable. Historically, research and development have not addressed
the priority health needs of those living in poverty. Alternative arrangements are
feasible and reforms are urgently required. Indeed, they are demanded by legal
and ethical duties, including those arising from international human rights law.
Millennium Development Goals, such as reducing child mortality, improving
maternal health, and combating HIV/AIDS, malaria and other diseases, depend
upon improving access to medicines. Indeed, one of the Millennium Development
Goal targets is to provide, “in cooperation with pharmaceutical companies, access
to affordable essential drugs in developing countries”.6 Crucially, implementation
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of the right to the highest attainable standard of health can help to achieve the
health related Goals.
Medical care in the event of sickness, as well as the prevention, treatment
and control of diseases, are central features of the right to the highest attainable
standard of health (the terms the “right to the highest attainable standard of
health” and “right to health” are used as a convenient abbreviation for the more
accurate formulation of the “right of everyone to the enjoyment of the highest
attainable standard of physical and mental health”).7 These features depend upon
access to medicines. Thus, access to medicines forms an indispensable part of the
right to the highest attainable standard of health. Numerous court cases, as well
as resolutions of the UN Commission on Human Rights, confirm that access to
essential medicines is a fundamental element of the right to health.8 Some of the
cases also confirm that access to essential medicines issues are closely connected
to other human rights, such as the right to life.
This article briefly examines the medicines component of the right to health.
While the article focuses upon the responsibilities of States, it also provides a
brief introduction to the responsibilities of pharmaceutical companies. The article
is offered as a preliminary contribution to far-reaching human rights issues of
the first importance.
The right-to-health analytical framework
In recent years, the UN Committee on Economic, Social and Cultural Rights,
WHO, the UN Special Rapporteur on the right of everyone to the enjoyment of
the highest attainable standard of physical and mental health, civil society
organizations, academics and many others, have developed a way of “unpacking”
or analysing the right to health with a view to making it easier to understand and
apply to health-related policies, programmes and projects in practice. The
analytical framework that has been developed is made up of ten key elements
and has general application to all aspects of the right to health, including the
underlying determinants of health: this has been demonstrated by the Special
Rapporteur in his use of the framework throughout his work.
While the analytical framework is set out in more detail elsewhere,9 its key
elements may be very briefly summarized as follows:
(a) Identification of the relevant national and international
human rights laws, norms and standards;
(b) Recognition that the right to health is subject to resource
constraints and progressive realization, requiring the
identification of indicators and benchmarks to measure
progress (or the lack of it) over time;
PAUL HUNT and RAJAT KHOSLA
101Year 5 • Number 8 • São Paulo • June 2008 ■
(c) Nonetheless, recognition that some obligations arising from
the right to health are subject to neither resource constraints
nor progressive realization, but are of immediate effect, for
example, the obligation to avoid de jure and de facto
discrimination;
(d) Recognition that the right to health includes freedoms (e.g.
freedom from non-consensual treatment and non-consensual
participation in clinical trials) and entitlements (e.g. to a
system of health care and protection). For the most part,
freedoms do not have budgetary implications, while
entitlements do;
(e) All health services, goods and facilities shall be available,
accessible, acceptable and of good quality;
(f ) States have duties to respect, protect and fulfil the right to
the highest attainable standard of health;
(g) Because of their crucial importance, the analytical framework
demands that special attention is given to issues of non-
discrimination, equality and vulnerability;
(h) The right to health requires that there is an opportunity for
the active and informed participation of individuals and
communities in decision making that bears upon their health;
(i) Developing countries have a responsibility to seek
international assistance and cooperation, while developed
States have some responsibilities towards the realization of the
right to health in developing countries; and
(j) The right to health requires that there are effective,
transparent and accessible monitoring and accountability
mechanisms available at the national and international levels.
By way of illustration, this article briefly applies elements of this analytical
framework to access to medicines.
B. The responsibilities of States
Ensuring medicines are available, accessible,
culturally acceptable and of good quality10
States have to do all they reasonably can to make sure that existing medicines
are available in sufficient quantities in their jurisdictions. For example, they
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might have to make use of the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) flexibilities by passing and using
compulsory licence legislation, thereby ensuring that medicines reach their
jurisdictions in adequate quantities. Historically, research and development
have not addressed the priority health needs of low-income and middle-income
countries. Thus, within a framework of international assistance and cooperation,
States are required to take effective measures to promote the development and
availability of new drugs, vaccines and diagnostic tools for those diseases causing
a heavy burden in developing countries.11 States therefore are required to resort
to a variety of economic, financial and commercial incentives in order to
influence research and development into specific health needs.
In short, States not only have a duty to ensure that existing medicines are
available within their borders, they also have a responsibility to take reasonable
measures to ensure that much-needed new medicines are developed and thereby
become available.
In addition to being available, medicines must also be accessible.
Accessibility has four dimensions. First, medicines must be accessible in all
parts of the country (for example, in remote rural areas as well as in urban
centres). This has major implications for the design of medicine supply
systems, including outreach programmes. Second, medicines must be
economically accessible (i.e. affordable) to all, including those living in
poverty. This has major implications for medicine funding and pricing
arrangements. It may also mean that a State has to revisit import duties and
other taxes on medicines if they are helping to take medicines beyond the
reach of  the poor.  Third,  medic ines  must  be access ib le  without
discrimination on any of the prohibited grounds, such as sex, race, ethnicity
and socio-economic status. As discussed in the next section, the principle
of non-discrimination may require a State to take measures to ensure equality
of access for all individuals and groups, such as disadvantaged minorities.
Fourth, reliable information about medicines must be accessible to patients
and health professionals so they can take well-informed decisions and use
medicines safely.
As well as being available and accessible, medicines and associated issues
must be culturally acceptable and respectful of medical ethics. For example,
national measures should support the proper use of traditional medicine and
its integration into health-care systems, while clinical trials must ensure the
informed consent of research subjects.
Medicines must also be of good quality. If rejected in the North because
they are beyond their expiry date and unsafe, medicines must not be recycled
to the South. Because medicines may be counterfeit or tampered with, States
must establish a regulatory system to check medicine safety and quality.
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Combating discrimination, inequality
and vulnerability
The right to health requires a national medicines policy to be designed to ensure
access for disadvantaged individuals and groups, including women and girls,
ethnic minority and indigenous populations, people living in poverty, people
living with HIV/AIDS, internally displaced people, the elderly, people with
disabilities, prisoners and others.
This preoccupation with vulnerability and disadvantage arises from two
of the most fundamental principles of international human rights law: non-
discrimination and equality. Importantly, these twin principles do not always
demand equal treatment; on the contrary, they sometimes require a State to
take measures in favour of disadvantaged individuals and communities.
Although closely linked to the ethical concept of equity, the principles of non-
discrimination and equality have the advantage of being reinforced by law and
accountability mechanisms.
In relation to access to medicines, non-discrimination and equality have
numerous implications. For example, a State is obliged to establish a national
medicine supply system that includes programmes specifically tailored to reach
the vulnerable and disadvantaged. It is also required to tackle the cultural,
social and political factors that inhibit vulnerable groups’ access to health care
generally and to medicines in particular. So far as possible, data must be
disaggregated to identify vulnerable groups and monitor their progress towards
equal access.12
In relation to medicines, how is progressive realization
to be measured and monitored? What are the obligations
of immediate effect?
The right to the highest attainable standard of health — and thus access to
medicines — is subject to progressive realization and resource availability, in
accordance with article 2 (1), of the International Covenant on Economic,
Social and Cultural Rights. Put simply, progressive realization means that a
State is required to be doing better in two years time than it is doing today,
while resource availability means that what is required of a developed State is
of a higher standard than what is required of a developing State.
This has a number of important implications. For example, States need
appropriate indicators and benchmarks so they know whether or not they are
progressively realizing the right to health.13 But it also has an important
qualification: the right to health includes some core obligations of immediate
effect, without which the right would be largely deprived of its raison d’être.14
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For example, States have an immediate obligation to avoid discrimination and
also to make certain pharmaceuticals — known as “essential medicines” —
available and accessible throughout their jurisdictions.15 These core obligations
of immediate effect are not subject to progressive realization.
Guided by the WHO Model List of Essential Medicines, a State is required
to prepare a national essential medicines list, by way of a participatory inclusive
process. If a State declines to prepare its own national essential medicines list,
the WHO model list will apply, subject to any obvious contextual revisions. A
State has a core obligation of immediate effect — not subject to progressive
realization — to make available and accessible throughout its jurisdiction the
essential medicines on its national list.16
In summary, the right to health encompasses access to non-essential and
essential medicines. While a State is required to progressively realise access to
non essential medicines, it has a core obligation of immediate effect to make
essential medicines available and accessible throughout its jurisdiction. This
article encompasses non-essential and essential medicines.
Duties to respect, protect and fulfil
States have duties to respect, protect and fulfil the right to the highest
attainable standard of health.17 For example, the duty to respect obliges a
State to ensure that its medicines policy does not discriminate against
women, ethnic minorities, or other disadvantaged groups. The duty to protect
requires a State to ensure that third parties do not obstruct enjoyment of
the right to health, for example, a State is required to ensure that
privatization in the health sector advances, and does not hinder, the
realization of the right to health. The duty to fulfil requires a State to provide
those living in poverty with essential medicines if they would otherwise be
unable to access them.
In other words, while a State may contract the delivery of health services
to a private company, it does not contract out of its right-to-health obligations.
A State always retains residual responsibility for the proper regulation of its
health and medicines systems, as well as for the well-being of the most
disadvantaged in its jurisdiction.
Participation in health policymaking
The active and informed participation of individuals and communities in health
policymaking that affects them is an important feature of the right to the highest
attainable standard of health. In most cases, a local community will have a
keen sense of its health priorities; it is entitled to participate in the identification
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of priorities and targets that guide the technical deliberations underlying the
policy formulation that will affect its members.
When formulating its national medicine policy and programmes, a State
is required to take steps to ensure the active and informed participation of all
those affected, not only professional associations and universities, but also rural
communities, non-governmental organizations, patients and consumer
associations, and representatives of disadvantaged groups.
International assistance and cooperation in health
The primary obligation for implementing the right to health falls upon the
national authorities in the State in question. However, States have the obligation
to take steps individually and through international assistance and cooperation
towards the full realization of various rights, including the right to health.18
In the context of medicines, this responsibility means that no rich State
should encourage a developing country to accept intellectual property standards
that do not take into account the safeguards and flexibilities included under
the TRIPS Agreement.19 In other words, developed States should not encourage
a developing country to accept “TRIPS-plus” standards in any bilateral or
multilateral trade agreement.20 They should help developing countries establish
effective, integrated, inclusive health systems that include reliable medicine
supply systems delivering quality affordable medicines for all, and support
research and development into the priority health needs of developing countries.
Monitoring and accountability
The right to health brings with it the crucial requirement of establishing
accessible, transparent and effective mechanisms of monitoring and
accountability. Those with right-to-health responsibilities must be held to
account in relation to the discharge of their duties, with a view to identifying
successes and difficulties; so far as necessary, policy and other adjustments can
then be made. There are many different forms of monitoring and accountability
mechanisms. While a State will decide which are most appropriate in its
particular case, all mechanisms must be effective, accessible and transparent.
A national medicines policy should therefore be subjected to appropriate
monitoring and accountability. This requires that the policy set out: the
Government’s right-to health obligations in relation to medicines; an
implementation plan that identifies objectives, timelines, duty holders and their
responsibilities, indicators, benchmarks, and reporting procedures. From time
to time, a suitable national body (e.g. a health ombudsman) will have to consider
the degree to which those responsible for the implementation of the national
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medicines policy have fulfilled their duties — not with a view to sanction and
punishment, but with a view to establishing which policies and institutions are
working and which are not, with the aim of improving the realization of the
right to medicines for all.
A selection of specific, practical issues
regarding access to medicines
Ensuring access to medicines for all gives rise to a wide range of specific, practical
and important issues. By way of illustration, this section briefly introduces
four of these issues, keeping in mind the analytical framework signalled in the
preceding paragraphs.
A reliable system for the supply of good
quality affordable medicines
Whether it chooses a supply system that is public, private or mixed, a State
has a legal obligation to ensure that there is a reliable, efficient, transparent
system for the supply of quality affordable medicines throughout its
jurisdiction. The supply system must be attuned to current needs, obtain
good value for money, minimize waste and avoid corruption. Crucially, it
must be designed to serve those living in poverty and isolated communities,
as well as wealthy urban elites.
Of course, this obligation is subject to the resources available in a particular
country: Canada is obliged to ensure better access to a wider range of medicines
than Chad. However, the obligation of both developed and developing States
is subject to progressive realization: all States are required to ensure better access
to a wider range of medicines in two years’ time than exists today.
To measure this progressive realization (or lack of it), States must develop
disaggregated indicators and benchmarks for a reliable, efficient medicine supply
system.21 These indicators have to reflect human rights features, for example,
the degree to which the system ensures equal access for disadvantaged groups
(hence the need for disaggregated indicators), and provides effective monitoring
and accountability mechanisms.
Quality of medicines
International human rights standards are clear: a State has a legal obligation to
ensure that medicines of good quality are available throughout its jurisdiction.
Thus, effective medicine regulation is required to ensure the safety, efficacy,
and quality of medicines available in both public and private sectors, as well as
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the accuracy and appropriateness of medicine information available to health
professionals and the public.
While the safety and quality of medicines is a problem in many developed
and developing States, the magnitude of the problem is much greater in
developing countries, where poor quality medicines may be the only ones to
reach the poor. In recent assessments carried out by WHO, 50-90 per cent of
anti-malarial drug samples failed quality control tests, while more than half of
antiretrovirals did not meet international standards.22 The sale of counterfeit
and substandard medicines remains a global concern.
One third of States have either no medicine regulatory authority or
inadequate capacity to regulate the medicines market.23 The absence of such an
authority is clearly inconsistent with the right to the highest attainable standard
of health. In line with their human rights responsibility of international
assistance and cooperation, developed States should actively help developing
countries establish appropriate medicine regulatory authorities.
Financing of medicines
Whether a medicine is affordable depends upon many factors, including
financing (i.e. how they are paid for) and pricing. There are different ways of
financing medicines, including by way of public or private health insurance,
patients’ fees, donations, loans, and so on. These are complex issues and here
the Special Rapporteur confines himself to one point. Whatever the chosen
financing arrangement, a State has a human rights obligation to ensure that
medicines are economically accessible (i.e. affordable) to all.
In many high-income countries, over 70 per cent of medicines are publicly
funded whereas in low- and middle-income countries public expenditure does
not cover the basic medicine needs of the majority of the population. In these
countries, patients themselves pay for 50 to 90 per cent of medicines. Where
the cost of medicines is borne by households, it can further impoverish already
disadvantaged populations, and inhibit equitable access to medicines.
In developed countries, a course of antibiotics for pneumonia may be
bought for the equivalent of two or three hours’ wages; in developing countries,
a course may cost one month’s wages.24 In developed countries, one year’s HIV
treatment may consume the equivalent of four to six months’ salary and, in
most cases, will be covered by health insurance; in many developing countries,
one year’s HIV paediatric treatment may consume the equivalent of an adult’s
income for 10 years. Such striking inequalities are deeply repugnant and
underscore the importance of developed States’ responsibility for international
assistance and cooperation.
For present purposes, however, the crucial point is that in developed
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countries most medicines are paid from public funding, whereas in developing
countries the majority of households buy their medicines with money from
their own pockets. In developing countries, inadequate public funding in the
health sector makes medicines less affordable, especially for those living in
poverty.
Corruption
In some medicine supply systems, corruption is endemic. Products are diverted;
unofficial “fees” are required for customs clearance; counterfeit medicines are
permitted to circulate and so on. Corruption can be deadly. As Dora Akunyili,
head of Nigeria’s Food and Drug Authority, put it: “drug counterfeiting,
facilitated by corruption, kills en masse and anybody can be a victim”.25
Those living in poverty are disproportionately affected by corruption in
the health sector because they are less able to afford small bribes for services
that are meant to be free, or to pay for private alternatives where corruption
has depleted public health services.
The right to health includes participation, access to information,
transparency, monitoring and accountability. Each of these features helps to
establish an environment in which corruption cannot survive. In short, a right-
to-health policy is also an anti-corruption policy. Thus, the application of the
right to health can help to reduce corruption in health systems in general, as
well as medicine supply systems in particular.
Conclusion
It is crucial for all States to have an up-to-date national medicines policy and
detailed implementation plan. The policy should include a national list of
essential medicines. At the turn of the century, almost 100 States did not have
a national medicines policy.26 Two thirds of those with a policy did not have an
implementation plan.27 Under these circumstances it is difficult to argue how
any State can be in conformity with its right-to-health obligations if it does not
have an up-to-date and appropriate national medicines policy, implementation
plan and essential medicines list, prepared by way of a participatory inclusive
process.28
C. The responsibilities of pharmaceutical companies
The previous section emphasized the primary responsibility of States to
increase access to medicines. But, of course, this is a shared responsibility. If
there is to be an increase in access to medicines, numerous national and
PAUL HUNT and RAJAT KHOSLA
109Year 5 • Number 8 • São Paulo • June 2008 ■
international actors have an indispensable role to play. The Millennium
Development Goals recognize that pharmaceutical companies are among those
who share this responsibility. Goal 8, a global partnership for development,
has a number of targets, not least: “in cooperation with pharmaceutical
companies, provide access to affordable, essential drugs in developing
countries” (emphasis added).
A few years back, a British Government policy paper on access to
medicines elaborated on this point: “responsibility for increasing access to
essential medicines rests with the whole international community. Progress
depends on everyone working in partnership to build health systems in
developing countries, increase financing, make medicines more affordable,
and increase the amount of new medicines developed for diseases affecting
developing countries”.29 Significantly, the paper continued: “in this context
there is a particular role for pharmaceutical companies. As the producers of
existing, and developers of new, medicines they can — and do — make a
difference within their sphere of influence”.
The pharmaceutical sector has a profound impact on the implementation
of the right to the highest attainable standard of health. States and others have
criticized the pharmaceutical sector for setting prices too high, erratic drug
donations, imbalanced research and development, lobbying for TRIPS plus
standards, inappropriate drug promotion, problematic clinical trials, and other
practices that are seen to obstruct a State’s ability to discharge its right to health
responsibilities.30 However, States and others have also commended some
significant progress in recent years, such as the more widespread use of
differential pricing, predictable and sustainable drug donations, and a renewed
commitment to research and development into neglected diseases.31
There is congruity between corporate responsibility, good practices and
the right to health. While the right-to-health analytical framework (as outlined
before) is primarily designed for States, its application can help to identify
policy interventions that a pharmaceutical company can — and should — take
to improve access to medicines. The right to health can be promoted and
protected without recourse to the courts, by shaping good policies. While it is
commendable that some of the companies have joined corporate responsibility
self-reporting initiatives, they fall short of the independent accountability
mechanisms anticipated by human rights. (Some independent accountability
mechanisms are non-judicial, for example a Health Ombudsman.)
Although a number of pharmaceutical companies report on their
corporate citizenship or corporate responsibility activities, few make specific
references in their corporate mission statements to human rights in general,
or the right to health in particular. Even fewer appear to have carefully
examined their policies through the lens of the right to the highest attainable
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standard of health. This is a missed opportunity because all pharmaceutical
companies, whether large or small, research based or generic, and whether or
not their reach is global, would find it beneficial to adopt a rights-sensitive
approach to their businesses, as outlined in the excellent joint publication of
the Global Compact, Business Leaders Initiative on Human Rights and
OHCHR.32
In recent years, the general understanding of economic, social and
cultural rights has deepened. If this momentum is to be maintained, it is
necessary to move from general discussions about economic, social and
cultural rights to consideration of specific rights, in relation to specific
sectors, actors and issues. This is the point that has now been reached in
relation to pharmaceutical companies and the right to health. Today, general
statements about pharmaceutical companies and economic, social and
cultural rights provide the indispensable foundation for a more detailed
examination of specific right-to-health issues arising in the pharmaceutical
sector.  In short ,  i t  i s  t ime to explore fur ther the r ight-to-health
responsibilities of pharmaceutical companies that were acknowledged in
general terms by the UN Committee on Economic, Social and Cultural
Rights in its general comment 14, paragraph 42.
For this reason the UN Special Rapporteur has embarked on a process
of preparing draft Guidelines for States and pharmaceutical companies on
access to medicines.33 The draft Guidelines for pharmaceutical companies
consider specific issues, such as differential pricing, donations, research and
development for neglected diseases, public-private partnerships, drug
promotion, clinical trials, and corruption.34 As observed by the UN Special
Representative of the Secretary-General on the issue of human rights and
transnational corporations and other business enterprises: “it is essential to
achieve greater conceptual clarity with regard to the respective responsibilities
of States and corporations […] In doing so we should bear in mind that
companies are constrained not only by legal standards but also by social norms
and moral considerations.”35
Conclusion
A consensus is emerging that business enterprises, like all actors in society,
have some legal and ethical human rights responsibilities. According to its
Preamble, the Universal Declaration of Human Rights gives rise to some
human rights responsibilities for “every organ of society”, which must include
business enterprises.36 The United Nations Global Compact, with more than
2,300 participating companies, affirms that businesses should support and
respect the protection of international human rights.37 The Organization for
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Economic Cooperation and Development’s Guidelines for Multinational
Enterprises require businesses to “respect the human rights of those affected
by their activities consistent with the host Government’s obligations and
commitments”.38 While holding that the draft Norms on the Responsibilities
of Transnational Corporations and Other Business Enterprises with Regard
to Human Rights of the Sub-Commission on the Promotion and Protection
of Human Rights had no legal standing, the Commission on Human Rights
found that the Norms contained “useful elements and ideas”.39 Some national
courts have recognized the impact of pharmaceutical company pricing policies
on the human rights of patients.40 Significantly, some companies have prepared
their own guidelines and other statements explicitly affirming their human
rights responsibilities.41
Today, the key issues include, first, clarifying the scope and content of
these human rights responsibilities and, second, identifying which are legal
and which are ethical. The draft Guidelines are a modest endeavour focusing
on the first of these issues in the specific context of pharmaceutical companies.
As for the second, it is inconceivable that some human rights do not place
legal responsibilities on business enterprises.42
D. Conclusions
Today, the content of the right to the highest attainable standard of health is
becoming clearer. In 2000, the UN Committee on Economic, Social and
Cultural Rights developed a general framework that unpacked the right to
health in terms of freedoms and entitlements; health care and underlying
determinants of health; non-discrimination; participation; monitoring and
accountability, and so on.43 This article endeavours to apply the framework
to medicines, a health issue encompassed by the Millennium Development
Goals.
The right to health makes a number of important contributions to the
struggle to improve access to medicines. It sharpens analysis of the causes, as
well as the responsibilities of various stakeholders. Policies informed by the
right to health are likely to be more equitable, sustainable and effective. This
contribution is already recognized in the context of some health policies and
programmes.44 In relation to policy making about medicines, there is also a
growing appreciation of the positive contribution that can be made by taking
into account the right to the highest attainable standard of health.
Additionally, experience confirms that traditional human rights
techniques, including “naming and shaming” and taking court cases, continue
to have an indispensable role to play in the realization of various elements of
the right to health, not least access to medicines.
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RESUMO
O presente artigo analisa o acesso a medicamentos, em especial aqueles considerados
essenciais, como parte do direito a desfrutar do mais elevado nível possível de saúde. A partir
da estrutura analítica do direito à saúde elaborada nos últimos anos, a primeira parte deste
artigo concentra-se nos deveres atribuídos aos Estados. A segunda parte procura nos
introduzir à responsabilidade das empresas farmacêuticas.
PALAVRAS-CHAVE
Medicamentos – Direito à saúde – Direitos humanos – TRIPS – OMS
RESUMEN
Este artículo analiza el componente del derecho al disfrute del más alto nivel posible de salud
que se relaciona con el acceso a los medicamentos, incluyendo los medicamentos esenciales.
Utilizando el marco analítico del derecho a la salud que ha sido desarrollado en los años
recientes, la primera sección se concentra en las responsabilidades de los Estados. La segunda
sección provee una breve introducción a las responsabilidades de las compañías farmacéuticas.
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